The prognostic value of DNA ploidy in a total population of uterine sarcomas

Annals of Oncology

Volumn 20, Issue 6, 2009, Pages 1037-1041

  Kildal, W ^a,b   Abeler, V M ^a   Kristensen, G B ^a   Jenstad, M ^a,b   Thoresen, S O ^c   Danielsen, H E ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c CANCER REGISTRY OF NORWAY   (Norway)

Author keywords

DNA ploidy; Endometrial stromal sarcoma; Leiomyosarcoma; Prognostic factors; Uterine sarcomas

Indexed keywords

DNA;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM SARCOMA; FEMALE; GENOMIC INSTABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MITOSIS INDEX; OUTCOME ASSESSMENT; PLOIDY; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; TUMOR NECROSIS; TUMOR VOLUME; UTERUS SARCOMA;

EID: 66149132252     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn765     Document Type: Article

References (32)

1. Nordal RR, Thoresen SØ. Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality. Eur J Cancer 1997; 6: 907-911.
2. Packenham JP, du Manoir S, Schrock E et al. Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization. Mol Carcinog 1997; 4: 273-279.
3. Vardi JR, Tovell HM. Leiomyosarcoma of the uterus: Clinicopathologic study. Obstet Gynecol 1980; 4: 428-434.
4. Major FJ, Blessing JA, Silverberg SG et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 1993(4 Suppl)): 1702-1709.
5. Chang KL, Crabtree GS, Lim-Tan SK et al. Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases. Am J Surg Pathol 1990; 5: 415-438.
6. Evans HL, Chawla SP, Simpson C et al. Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. A study of 46 cases, with emphasis on diagnostic criteria and prognostic factors. Cancer 1988; 10: 2239-2247.
7. Nordal RR, Kjørstad KE, Stenwig AE et al. Leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS) of the uterus. A survey of patients treated in the Norwegian Radium Hospital 1976-1985. Int J Gynecol Cancer 1993; 2: 110-115.
8. Bodner K, Bodner-Adler B, Obermair A et al. Prognostic parameters in endometrial stromal sarcoma: A clinicopathologic study in 31 patients. Gynecol Oncol 2001; 2: 160-165.
9. Moinfar F, Azodi M, Tavassoli FA. Uterine sarcomas. Pathology 2007; 1: 55-71.
10. Blom R, Guerrieri C, Stål O et al. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. Gynecol Oncol 1998; 1: 54-61.
11. Kahanpaa KV, Wahlstrom T, Grohn P et al. Sarcomas of the uterus: A clinicopathologic study of 119 patients. Obstet Gynecol 1986; 3: 417-424.
12. Larson B, Silfverswärd C, Nilsson B et al. Prognostic factors in uterine leiomyosarcoma. A clinical and histopathological study of 143 cases. The Radiumhemmet series 1936-1981. Acta Oncol 1990; 2: 185-191.
13. Nordal RR, Kristensen GB, Kærn J et al. The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma. Acta Oncol 1995; 6: 797-802.
14. Fox H. Ploidy in gynaecological cancers. Histopathology 2005; 2: 121-129.
15. Nola M, Babic D, Ilic J et al. Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus. Cancer 1996; 12: 2543-2550.
16. Tsushima K, Stanhope CR, Gaffey TA et al. Uterine leiomyosarcomas and benign smooth muscle tumors: Usefulness of nuclear DNA patterns studied by flow cytometry. Mayo Clin Proc 1988; 3: 248-255.
17. Malmström H, Schmidt H, Persson P-G et al. Flow cytometric analysis of uterine sarcoma: Ploidy and S-phase rate as prognostic indicators. Gynecol Oncol 1992; 2: 172-177.
18. Jeffers MD, Oakes SJ, Richmond JA et al. Proliferation, ploidy and prognosis in uterine smooth muscle tumours. Histopathology 1996; 3: 217-223.
19. Blom R, Malmström H, Guerrieri C. Endometrial stromal sarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 17 cases. Int J Gynecol Cancer 1999; 2: 98-104.
20. Peters WA III, Howard DR, Andersen WA et al. Deoxyribonucleic acid analysis by flow cytometry of uterine leiomyosarcomas and smooth muscle tumors of uncertain malignant potential. Am J Obstet Gynecol 1992; 6 Pt 1: 1646-1653.
21. Nordal RR, Kristensen GB, Kærn J et al. The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma. Gynecol Oncol 1996; 2: 254-259.
22. Layfield LJ, Liu K, Dodge R et al. Uterine smooth muscle tumors: Utility of classification by proliferation, ploidy, and prognostic markers versus traditional histopathology. Arch Pathol Lab Med 2000; 2: 221-227.
23. Hendrickson MR, Tavassoli FA, Kempson WG. World Health Organization classification of tumors. In Tavassoli FA, Devilee P (eds): Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press 2003; 233-249.
24. Abeler VM, Røyne O, Thoresen SØ et al. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2008.
25. Kildal W, Kærn J, Kraggerud SM et al. Evaluation of genomic changes in a large series of malignant ovarian germ cell tumors-relation to clinicopathologic variables. Cancer Genet Cytogenet 2004; 1: 25-32.
26. Toledo G, Oliva E. Smooth muscle tumors of the uterus: A practical approach. Arch Pathol Lab Med 2008; 4: 595-605.
27. Gal R, Rath-Wolfson L, Rosenblatt Y et al. An improved technique for mitosis counting. Int J Surg Pathol 2005; 2: 161-165.
28. Silverberg SG. Reproducibility of the mitosis count in the histologic diagnosis of smooth muscle tumors of the uterus. Hum Pathol 1976; 4: 451-454.
29. Bertino B, Knape WA, Pytlinska M et al. A comparative study of DNA content as measured by flow cytometry and image analysis in 1864 specimens. Anal Cell Pathol 1994; 4: 377-394.
30. Rosenberg P, Wingren S, Guerrieri C. Flow cytometric DNA-heterogeneity in paraffin-embedded endometrial cancer. Acta Oncol 1997; 1: 23-26.
31. Robinson RA. Defining the limits of DNA cytometry. Am J Clin Pathol 1992; 3: 275-277.
32. Blom R, Guerrieri C. Adenosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53 and mdm-2 analysis of 11 cases. Int J Gynecol Cancer 1999; 1: 37-43.